Alberto M Borobia
Overview
Explore the profile of Alberto M Borobia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
1315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hernandez-Blanco C, Al-Akioui-Sanz K, Herrera L, Aguirre-Portoles C, Lozano-Ojalvo D, Perez-Rodriguez L, et al.
iScience
. 2025 Jan;
28(2):111698.
PMID: 39877904
The severity of COVID 19 symptoms has a direct correlation with lymphopenia, affecting natural killer (NK) cells. SARS-CoV-2 specific "memory" NK cells obtained from convalescent donors can be used as...
2.
Corominas J, Garriga C, Prenafeta A, Moros A, Canete M, Barreiro A, et al.
Vaccine
. 2025 Jan;
47:126685.
PMID: 39809095
The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority phase IIb clinical trial comparing the immunogenicity and safety of the PHH-1V adjuvanted recombinant vaccine as a heterologous booster against homologous...
3.
Stewart S, Seco-Meseguer E, Diago-Sempere E, Marin-Candon A, Carmona M, Estebanez M, et al.
BMJ Open
. 2024 Nov;
14(11):e089823.
PMID: 39510769
Introduction: Genetic variations impact drug response, driving the need for personalised medicine through pre-emptive pharmacogenetic testing. However, the adoption of pre-emptive pharmacogenetic testing for commonly prescribed drugs, such as statins,...
4.
Fuentes B, Jordi-Perea P, Sempere-Iborra C, Tarifa-Rodriguez A, De Celis-Ruiz E, Martin Alonso M, et al.
Digit Health
. 2024 Oct;
10:20552076241288311.
PMID: 39421311
Background: Helping people recover from aphasia is among the top 10 research priorities relating to life after stroke. Objective: We aimed to evaluate the feasibility of dubbing techniques (using newly...
5.
Garcia-Perez J, Borobia A, Perez-Olmeda M, Portoles A, Castano L, Campins-Arti M, et al.
iScience
. 2024 Sep;
27(9):110728.
PMID: 39286494
CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 ...
6.
Stewart S, Gomez Lopez de Las Huertas A, Jimenez-Gonzalez M, Carcas A, Borobia A, Ramirez E
J Clin Med
. 2024 May;
13(9).
PMID: 38731156
The drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome represents a severe form of drug hypersensitivity reaction characterized by significant morbidity, mortality, and long-term sequelae, coupled with limited therapeutic...
7.
Abad-Santos F, Alino S, Borobia A, Garcia-Martin E, Gasso P, Maronas O, et al.
Pharmacol Res
. 2024 Jan;
200:107061.
PMID: 38199278
The development of Pharmacogenetics and Pharmacogenomics in Western Europe is highly relevant in the worldwide scenario. Despite the usually low institutional support, many research groups, composed of basic and clinical...
8.
Garcia-Garcia I, Seco-Meseguer E, Borobia A, Carcas-Sansuan A
Expert Rev Clin Pharmacol
. 2023 Dec;
17(1):1-10.
PMID: 38088171
Introduction: The implementation of pharmacogenetic analysis within clinical trials faces methodological, ethical, and regulatory challenges, as well as tackling the difficulty in obtaining actionable information with a sufficient level of...
9.
Stewart S, Dodero-Anillo J, Guijarro-Eguinoa J, Arias P, Gomez Lopez de Las Huertas A, Seco-Meseguer E, et al.
Front Pharmacol
. 2023 Nov;
14:1292416.
PMID: 37927587
The field of pharmacogenetics (PGx) holds great promise in advancing personalized medicine by adapting treatments based on individual genetic profiles. Despite its benefits, there are still economic, ethical and institutional...
10.
Ferreras C, Hernandez-Blanco C, Martin-Quiros A, Al-Akioui-Sanz K, Mora-Rillo M, Ibanez F, et al.
Cytotherapy
. 2023 Oct;
26(1):25-35.
PMID: 37897472
Background Aims: There are currently no effective anti-viral treatments for coronavirus disease 2019 (COVID-19)-hospitalized patients with hypoxemia. Lymphopenia is a biomarker of disease severity usually present in patients who are...